Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Common Equity for 10 consecutive years, with $139.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 540.02% to $139.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.1 million through Dec 2025, up 540.02% year-over-year, with the annual reading at $139.1 million for FY2025, 540.02% up from the prior year.
  • Common Equity for Q4 2025 was $139.1 million at Rhythm Pharmaceuticals, down from $148.8 million in the prior quarter.
  • The five-year high for Common Equity was $380.9 million in Q1 2021, with the low at -$11.9 million in Q2 2025.
  • Average Common Equity over 5 years is $175.7 million, with a median of $189.0 million recorded in 2022.
  • Peak annual rise in Common Equity hit 1226.95% in 2025, while the deepest fall reached 130.27% in 2025.
  • Over 5 years, Common Equity stood at $284.2 million in 2021, then fell by 7.0% to $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then crashed by 87.2% to $21.7 million in 2024, then soared by 540.02% to $139.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $139.1 million, $148.8 million, and -$11.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.